Wednesday, February 16, 2022 11:44:13 AM
Feb. 16, 2022 8:37 AM ETTetra Bio-Pharma Inc. (TBPMF)By: Ravikash, SA News Editor
Tetra Bio-Pharma (OTCQB:TBPMF) announced the approval of a C$4.5M participative loan from the ministère de l'Économie et de l'Innovation under the BioMed Propulsion Program, managed by Investissement Québec.
The company said the funding will support the development of ARDS-003 for acute respiratory distress syndrome whether or not it is caused by COVID-19; as well as in patients with Sepsis.
This company noted that the transaction is conditional on the approval of all shareholders and will be subject to a vote at the General Meeting in May 2022 since it will require the transfer of its head office from Ontario to the province of Quebec and the approval of certain financial terms.
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM